Prosecution Insights
Last updated: April 19, 2026

Navigo Proteins GmbH

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18556860 NOVEL HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) SPECIFIC BINDING MOLECULES MELCHIOR, JAMES RYLAND 1644 Non-Final OA Oct 23, 2023
18036142 NEW TYPE II COLLAGEN BINDING PROTEINS PUTTLITZ, KARL J 1646 Non-Final OA May 09, 2023
18016436 SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS DAHLE, CHUN WU 1641 Non-Final OA Jan 16, 2023
18012281 BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) JADHAO, SAMADHAN JAISING 1672 Non-Final OA Dec 22, 2022
18012284 BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) SALVOZA, M FRANCO G 1672 Final Rejection Dec 22, 2022

Managing Navigo Proteins GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month